AnaptysBio, Inc. (NASDAQ:ANAB) Director Acquires $842,177.28 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc purchased 65,184 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the transaction, the director now directly owns 7,860,180 shares in the company, valued at approximately $101,553,525.60. This trade represents a 0.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 6,646 shares of AnaptysBio stock. The shares were bought at an average price of $12.95 per share, with a total value of $86,065.70.

AnaptysBio Stock Performance

ANAB opened at $14.60 on Friday. The company has a market capitalization of $444.26 million, a PE ratio of -2.40 and a beta of -0.11. The stock’s fifty day moving average is $19.75 and its 200-day moving average is $28.43. AnaptysBio, Inc. has a one year low of $12.51 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of recent research reports. HC Wainwright cut AnaptysBio from a “buy” rating to a “neutral” rating and cut their target price for the company from $52.00 to $19.00 in a research note on Wednesday, December 11th. UBS Group lifted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Wells Fargo & Company dropped their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.45.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its position in AnaptysBio by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 74,510 shares of the biotechnology company’s stock worth $1,867,000 after buying an additional 10,423 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 525 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of AnaptysBio by 67.3% in the 2nd quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company’s stock worth $947,000 after acquiring an additional 15,200 shares during the last quarter. Headlands Technologies LLC raised its position in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of AnaptysBio by 52.4% during the second quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock valued at $3,827,000 after purchasing an additional 52,502 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.